FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies

FDA granted accelerated approval to Enhertu for the treatment of adults with unresectable or metastatic HER2-positive breast cancer

Read the full article here

Related Articles

Registration

Register for Cleveland Clinic’s Comprehensive Cancer Center Medical Oncology Update 2025 on Wednesday June 18 at the Intercontinental Hotel and Conference Center in Cleveland OH